Therefore, intravitreal humanized monoclonal antibodies (huMAb) against VEGF, such as ranibizumab and aflibercept, have being used for PRD, AMD, ROP, macular edema after retinal vein occlusion, vitreous hemorrhage, neovascular glaucoma, among other retinovascular diseases [6]. Here, VEGFA is linked to age-related macular degeneration.